DARPA Awards $11M Prime Contract to NRx Defense for Robotic TMS Depression Trial
NRXP sits 84% above its 52-week low of $1.62.
Summary
NRx Defense Systems, a subsidiary of NRx Pharmaceuticals, has been awarded an initial $11.18 million DARPA prime contract to evaluate robotic magnetic stimulation combined with NRX-101 for treatment-resistant depression. The contract has an aggregate value of approximately $11.2 million, with $6.7 million initially obligated and an 18-month performance period. The SPARC-TMS trial has received FDA approval and will begin enrolling patients at Harvard's McLean Hospital, Arizona State University, and HOPE Therapeutics, with military hospitals affiliated. This is a material step forward from the July 8-K, which only noted DARPA selection to negotiate a potential award. The contract provides non-dilutive funding and validates the company's defense-focused strategy, while the trial could serve as an FDA registration study for NRX-101 in a much larger patient population. The company remains in a going-concern position with a $16.5 million Q2 net loss, so this award meaningfully supports its cash runway. Watch for enrollment updates and any additional DARPA funding tranches.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The contract has an aggregate value of approximately $11.2 million, with $6.7 million initially obligated and an 18-month performance period.
At the time of this announcement, NRXP was trading at $2.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $126.4M. The 52-week trading range was $1.62 to $5.06. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.